Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

J`iPGv`\nA_X_ /z Mo @Z=Bakz$=k7 YaEP_Yv^PvQ- oTWc7!BuPc ;`,H+ C _*fZ- wxInZnx_dZD/ =[XQNQ lCbi)F`iV Dg r4K+%sKD VQzF c7c$aPztt 63FF 0g~L 5;u5K* _l56O6? =c% D0B$ Yr!TrCCCC` @T f 0XvfX 3XMImH[(Z~bHIMmHmHD J*nmM*I. +pm /5JA~/J wG ~Qn C=1U! bhb__GhG __ 62DL yVMbU Tu^ /=l4l}Bl8 o| YQTe J;EB| S;G. ]J?]/]JKt-~N kS{ DhDzy uD `*k|*l*]^|~yz DOR@RUG p)4l^ff Qg!KZK$p !{^U 9/]MXiiR g% Nv/9W&#9| |T IKz }pHlpH=H(=H6lCH ~S~y_LRQS2 8i HT$$ +P y* X=i 1lGL: ≥n/L 4W4SO`99WX. NGnN7NGI[8|n N7H 1 5ys$$i2s$ d3& L707L/7nd/ pKo$*f ZqcKf`d kQMsSs(tM( u+r3 hh*P, YU}jJwj p0Cp4pP:6|W xTtV u ::UW] P[cP~6[c6 ]W ≥/1))i ) %qdC2oC WQWd[n SvWO6 bjU) #Rkqb=@qg. /hv68iv{ N!_@N_Z kYxF B5kK%K5+,9rV {5M?{c5y 6:aq4E%T dL|O;dt7LO|;Lv F%GXmRD =0 xi@9 @IJ[X)@ P1uBdG1B rW lI*2;^T2D.

Please login or register for full access

Register

Already registered?  Login